health benefits of glp-1 agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Glucagon-like peptide 1 receptor agonists:
Description
Various studies have found that, among patients with type 2 diabetes, a history of myocardial infarction or stroke, or arteriosclerotic cardiovascular disease, liraglutide use was associated with a lower incidence of cardiovascular disease than in the control group [16]
In the ELIXA trial, Pfeffer et al 27 evaluated the effect of lixisenatide in patients with type 2 diabetes with myocardial infarction or unstable angina admission in the previous 180 days
Guardian Australia contacted the Maementcurves.com site for comment
17 Long-term effects of GLP-1 in animal studies demonstrated increases in beta-cell mass and beta-cell efficiency
Instead, discuss implementing a bone health protection plan alongside your treatment
